We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Repligen (RGEN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Repligen is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RGEN is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RGEN's full-year earnings has moved 5.92% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, RGEN has moved about 57.79% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 4.07% on a year-to-date basis. This means that Repligen is outperforming the sector as a whole this year.
To break things down more, RGEN belongs to the Medical - Biomedical and Genetics industry, a group that includes 376 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, stocks in this group have gained 2.02% this year, meaning that RGEN is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RGEN. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Repligen (RGEN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Repligen is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RGEN is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RGEN's full-year earnings has moved 5.92% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, RGEN has moved about 57.79% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 4.07% on a year-to-date basis. This means that Repligen is outperforming the sector as a whole this year.
To break things down more, RGEN belongs to the Medical - Biomedical and Genetics industry, a group that includes 376 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, stocks in this group have gained 2.02% this year, meaning that RGEN is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RGEN. The stock will be looking to continue its solid performance.